A comparative study of the safety, efficacy, quality of life and pharmacoeconomics of levetiracetam with controlled-release carbamazepine in patients of new onset focal seizures: A randomized controlled academic trial

IF 0.9 4区计算机科学 Q3 COMPUTER SCIENCE, THEORY & METHODS

International Journal of Parallel Programming Pub Date : 2021-04-15 DOI:10.18231/J.IJPP.2021.006

D. Kansal, N. Patiyal, A. Bhardwaj, A. Sood, Sushma Sawaraj, Ankit Chauhan, Palvi Mittal

{"title":"A comparative study of the safety, efficacy, quality of life and pharmacoeconomics of levetiracetam with controlled-release carbamazepine in patients of new onset focal seizures: A randomized controlled academic trial","authors":"D. Kansal, N. Patiyal, A. Bhardwaj, A. Sood, Sushma Sawaraj, Ankit Chauhan, Palvi Mittal","doi":"10.18231/J.IJPP.2021.006","DOIUrl":null,"url":null,"abstract":"Background: Carbamazepine is used widely in focal seizures but has the disadvantage of frequent drug interactions. Levetiracetam is a novel antiseizure drug with better pharmacokinetic profile with less drug interactions and having broader therapeutic range.\nAims: The aim of our study was to generate more evidence for better management of focal seizures with available anti-seizure monotherapy.\nMaterials and Methods: It was a randomized, prospective, open label, comparative interventional study, conducted at Dr. R.P.G.M.C, Kangra at Tanda. 38 participants received tablet levetiracetam (LEV) 1000 mg/day and 36 participants received tablet controlled-release carbamazepine (CBZ-CR) 600 mg/day.\nResults: CBZ-CR group had significantly higher CNS depression as compared to LEV (p=0.027). Hematological adverse effects with CBZ-CR were reversible. Both the drugs were safe on kidney and liver. 22 (66.7%) patients in LEV group and 26 (78.8%) in CBZ-CR group remained seizure free. QOL: Both the drugs significantly improved QOL. Pharmacoeconomics: CBZ-CR costed significantly lower than LEV (p\nConclusion: Both the drugs are well tolerated and equally efficacious in controlling focal seizures. Quality of- life has improved significantly in both the groups. CBZ-CR is pharmacoeconomically better than LEV for treatment of new onset focal seizures in adult patients.\n\nKeywords: Controlled release carbamazepine, Epilepsy, Focal seizure, Levetiracetam, Pharmacoeconomics.","PeriodicalId":14313,"journal":{"name":"International Journal of Parallel Programming","volume":"8 1","pages":"35-41"},"PeriodicalIF":0.9000,"publicationDate":"2021-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Parallel Programming","FirstCategoryId":"94","ListUrlMain":"https://doi.org/10.18231/J.IJPP.2021.006","RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"COMPUTER SCIENCE, THEORY & METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Carbamazepine is used widely in focal seizures but has the disadvantage of frequent drug interactions. Levetiracetam is a novel antiseizure drug with better pharmacokinetic profile with less drug interactions and having broader therapeutic range. Aims: The aim of our study was to generate more evidence for better management of focal seizures with available anti-seizure monotherapy. Materials and Methods: It was a randomized, prospective, open label, comparative interventional study, conducted at Dr. R.P.G.M.C, Kangra at Tanda. 38 participants received tablet levetiracetam (LEV) 1000 mg/day and 36 participants received tablet controlled-release carbamazepine (CBZ-CR) 600 mg/day. Results: CBZ-CR group had significantly higher CNS depression as compared to LEV (p=0.027). Hematological adverse effects with CBZ-CR were reversible. Both the drugs were safe on kidney and liver. 22 (66.7%) patients in LEV group and 26 (78.8%) in CBZ-CR group remained seizure free. QOL: Both the drugs significantly improved QOL. Pharmacoeconomics: CBZ-CR costed significantly lower than LEV (p Conclusion: Both the drugs are well tolerated and equally efficacious in controlling focal seizures. Quality of- life has improved significantly in both the groups. CBZ-CR is pharmacoeconomically better than LEV for treatment of new onset focal seizures in adult patients. Keywords: Controlled release carbamazepine, Epilepsy, Focal seizure, Levetiracetam, Pharmacoeconomics.

查看原文本刊更多论文

左乙拉西坦与控释卡马西平治疗新发局灶性癫痫患者的安全性、有效性、生活质量和药物经济学比较研究:一项随机对照学术试验

背景：卡马西平广泛用于局灶性癫痫发作，但存在药物相互作用频繁的缺点。左乙拉西坦是一种新型的抗癫痫药物，具有更好的药代动力学特征，药物相互作用较少，治疗范围更广。目的：我们研究的目的是为使用可用的抗癫痫单一疗法更好地管理局灶性癫痫提供更多证据。材料和方法：这是一项随机、前瞻性、开放标签、比较介入研究，由坦达Kangra的R.P.G.M.C博士进行。38名参与者接受1000 mg/天的左乙拉西坦（LEV）片剂治疗，36名参与者接受600 mg/天控释卡马西平（CBZ-CR）片剂治疗。结果：与LEV相比，CBZ-CR组的中枢神经系统抑郁显著增加（p=0.027）。CBZ-CR的血液学不良反应是可逆的。这两种药物对肾脏和肝脏都是安全的。LEV组22例（66.7%）和CBZ-CR组26例（78.8%）患者保持无癫痫发作。生活质量：两种药物均显著改善生活质量。药物经济学：CBZ-CR的成本显著低于LEV（结论：两种药物均具有良好的耐受性，在控制局灶性癫痫发作方面同样有效。两组患者的生活质量均显著提高。CBZ-CR在治疗成年患者新发局灶性发作方面在药物经济学上优于LEV。关键词：控释卡马西平、癫痫、局灶性惊厥、左乙拉西坦、药物经济学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Parallel Programming 工程技术-计算机：理论方法

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： International Journal of Parallel Programming is a forum for the publication of peer-reviewed, high-quality original papers in the computer and information sciences, focusing specifically on programming aspects of parallel computing systems. Such systems are characterized by the coexistence over time of multiple coordinated activities. The journal publishes both original research and survey papers. Fields of interest include: linguistic foundations, conceptual frameworks, high-level languages, evaluation methods, implementation techniques, programming support systems, pragmatic considerations, architectural characteristics, software engineering aspects, advances in parallel algorithms, performance studies, and application studies.